AANEM Annual Meeting
The Neurology Today Conference Reporter aims to keep neurologists up-to-date and fully informed about the most noteworthy news from major professional meetings.
Whether you are attending the meeting or reading about it remotely, you'll be able to access daily, concise peer-reviewed reports from major neurology conferences via email blasts that are optimized for web and mobile viewing.
Neurology Today Conference Reporter highlights only those papers and presentations deemed noteworthy by the
Neurology Today editors. All reports are vetted and reviewed by our team of neurologist reviewers, as well. Each report includes commentary from independent experts.
Peer-reviewed by the
Neurology Today Editors
From left to right: Editor-in-Chief Joseph E. Safdieh, MD, FAAN, assistant dean, clinical curriculum, Louis and Rachel Rudin Foundation Education Scholar, vice chairman for education, associate professor of neurology, Weill Cornell Medical College; Associate Editor Orly Avitzur, MD, MBA, FAAN, clinical assistant professor of neurology, New York Medical College; Associate Editor Deborah A. Hall, MD, PhD, FAAN, associate professor in the department of neurological sciences, Rush University Medical Center; Associate Editor Barney J. Stern, MD, FAAN, vice chair for strategic planning in the department of neurology, Johns Hopkins University; and Norman Latov, MD, PhD, professor of neurology and neuroscience, and director of the Peripheral Neuropathy Clinical and Research Center at the Weill Medical College of Cornell University.
Hot off the press from the 2018 AANEM Annual Meeting:
October 18—What You Should Know About a Rare Variant of Guillain-Barré Syndrome
October 18—Thymectomy May Not Offer Additional Benefit Over Rituximab for MuSK Myasthenia Gravis
October 18—A Proposal to Support a Training Rotation in Autonomic Nervous System Disorders
October 17—Voted 'Best Abstract': Data from the Largest Natural History Study of Stiff Person Syndrome
October 17—For Neurology Residents, Electrodiagnostic Training Ranges from Good to None
October 17—Nearly Half of Duchenne Muscular Dystrophy Patients Are Candidates for Gene Therapies